<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02025049</url>
  </required_header>
  <id_info>
    <org_study_id>Ptcl-01501</org_study_id>
    <nct_id>NCT02025049</nct_id>
  </id_info>
  <brief_title>DP-b99 in the Treatment of Acute High-risk Pancreatitis</brief_title>
  <official_title>Pilot Trial of Intravenous DP-b99 in the Treatment of First-ever Episode of Non-obstructive Acute High-risk Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>D-Pharm Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>D-Pharm Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammation of the pancreas often leads to severe damage not only to the pancreas but also&#xD;
      to other organs in the abdomen as well as to complications in organs further away like the&#xD;
      lung and the kidney. This trial will examine if DP-b99, given to patients with non-severe&#xD;
      inflammation of the pancreas, can mitigate the development of processes that can lead to&#xD;
      serious complications of this disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a randomised, double blind, placebo-controlled, multi-centre,&#xD;
      multi-national, parallel-arm study comparing a placebo group to a DP-b99 group treated&#xD;
      intravenously with 1.0 mg/kg twice daily for 2 consecutive days.&#xD;
&#xD;
      The study will enrol 30 patients at high risk of developing severe pancreatitis, as assessed&#xD;
      by the Bedside Index for Severity in Acute Pancreatitis (BISAP) score of 3 or more at study&#xD;
      entry.&#xD;
&#xD;
      The primary study endpoint is the effect of DP-b99 on systemic inflammation in acute&#xD;
      pancreatitis as reflected by C-reactive protein (CRP) plasma levels. The secondary endpoints&#xD;
      are the safety of DP-b99 in this population of patients (through routine safety laboratory&#xD;
      tests, physical examination and vital signs monitoring, ECG and adverse event reporting),&#xD;
      DP-b99's effects on other plasma inflammatory markers (interleukin-6, matrix&#xD;
      metalloproteinase 9, tumor necrosis factor alpha) as well as its effects on the clinical&#xD;
      course of pancreatitis (based on changes in the Systemic Inflammatory Response Syndrome&#xD;
      (SIRS) and Acute Physiology And Chronic Health Evaluation II (APACHE II) scores, and on&#xD;
      contrast material-enhanced abdominal Computerised Tomography (CT), versus placebo.&#xD;
&#xD;
      Clinical trial material administration will begin within 48 hours of acute pancreatitis&#xD;
      symptoms onset. Subjects will be randomised at a ratio of 1:1 to receive either DP b99 or&#xD;
      placebo. The serum levels of DP-b99 at the end of each 2-hour infusion will also be&#xD;
      monitored.&#xD;
&#xD;
      The study duration per individual subject will be 14 days, consisting of a screening&#xD;
      evaluation followed by a 48-hour double blind treatment period, which will be part of an&#xD;
      in-hospital observation period of at least 6 days, and a follow-up final visit on Day 14.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment&#xD;
  </why_stopped>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-reactive protein serum concentration</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Pancreatitis</condition>
  <arm_group>
    <arm_group_label>DP-b99</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous DP-b99, 1.0 mg/kg twice daily for 2 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous placebo (mannitol based, DP-b99 look-alike) twice daily for 2 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DP-b99</intervention_name>
    <description>DP-b99 is a lipophilic analog of the divalent metal ion chelator O,O'-Bis(2-aminophenyl) ethyleneglycol-N,N,N',N'-tetraacetic acid (BAPTA)</description>
    <arm_group_label>DP-b99</arm_group_label>
    <other_name>Chemical name: 1,2-Bis(2-aminophenoxy)ethane- N,N,N'N'-tetraacetic acid, N,N'-di(octyloxyethyl ester), N,N'-disodium salt</other_name>
    <other_name>CAS Number: 222315-66-4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>mannitol-based DP-b99 look-alike</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subject.&#xD;
&#xD;
          -  Age 18 years or higher.&#xD;
&#xD;
          -  First in a lifetime episode of acute pancreatitis.&#xD;
&#xD;
          -  Diagnosis of acute pancreatitis based on 2 of the following 3 criteria: (1) typical&#xD;
             upper abdominal pain; (2) elevation of serum amylase and/or lipase at least 3 times&#xD;
             the upper limit of normal; (3) contrast-material enhanced CT scan or abdominal&#xD;
             sonogram demonstrating changes of acute pancreatitis&#xD;
&#xD;
          -  History supporting alcoholic, hypertriglyceridemic or biliary etiology of the current&#xD;
             pancreatitis episode (for biliary pancreatitis, a sonogram must exclude a stone&#xD;
             obstruction at the time of study screening).&#xD;
&#xD;
          -  BISAP score of 3 or higher&#xD;
&#xD;
          -  Study treatment initiation is possible within 48 h of symptom onset&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Drug-induced, viral, hereditary or post-ERCP pancreatitis.&#xD;
&#xD;
          -  Recurrent episode of pancreatitis.&#xD;
&#xD;
          -  CT evidence of pancreatic necrosis at study entry.&#xD;
&#xD;
          -  Imaging evidence of physical obstruction of the common bile duct at study entry; e.g.&#xD;
             for abdominal sonogram, stone(s) in the common bile duct or common bile duct having&#xD;
             diameter less than 6 mm (above 80 years, less than 8 mm) with gallbladder in situ.&#xD;
&#xD;
          -  Severe chronic renal failure (Modification of Diet in Renal Disease formula 30 mL/min&#xD;
             or dependency on renal dialysis).&#xD;
&#xD;
          -  High likelihood for an invasive intra-biliary tract intervention (e.g. ERCP) in the&#xD;
             coming week.&#xD;
&#xD;
          -  Class II or greater New York Heart Association heart failure.&#xD;
&#xD;
          -  Oxygen-dependent chronic obstructive pulmonary disease (COPD).&#xD;
&#xD;
          -  Cirrhosis of the liver.&#xD;
&#xD;
          -  Severe anemia (hemoglobin less than 8 g/dL).&#xD;
&#xD;
          -  Hematocrit below 35 % or above 45 % at study entry (fluids may be administered to&#xD;
             correct the hematocrit before randomisation as long as study treatment starts within&#xD;
             48 hours of symptoms onset).&#xD;
&#xD;
          -  Serum alanine aminotransferase above 250 IU/L at study entry.&#xD;
&#xD;
          -  Clinical suspicion of ascending cholangitis at study entry.&#xD;
&#xD;
          -  Active gastrointestinal bleeding.&#xD;
&#xD;
          -  Current malignancy not in remission (other than basal cell carcinoma of skin).&#xD;
&#xD;
          -  Altered mental status.&#xD;
&#xD;
          -  Current breastfeeding or pregnancy.&#xD;
&#xD;
          -  Female of childbearing potential (less than 2 years postmenopausal or not surgically&#xD;
             sterilized) who is not willing to use adequate and effective birth control measures&#xD;
&#xD;
          -  Known hypersensitivity to any component of the investigational product.&#xD;
&#xD;
          -  Dependent relationship with the investigator or the sponsor.&#xD;
&#xD;
          -  Participation in an investigational drug study during this clinical trial or within 30&#xD;
             days prior to start of this clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilad Rosenberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>D-Pharm Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University Hospital Brno, Gastroenterology Clinic</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>December 25, 2013</study_first_submitted>
  <study_first_submitted_qc>December 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2013</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

